Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Resistant Ocular Lesions in Behcet's Disease
NCT00664599Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2006
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Behcet's disease (BD), sponsored by Tehran University of Medical Sciences. Started Apr 2006; status: completed.
02
Drugs
rituximab
03
Conditions
Behcet's disease (BD)
Beyond the preview
Go deeper on NCT00664599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00664599.